Each quarter we compile key statistics and trends on strategic transactions and financing. 
 
Our Q3 report analyzes current trends of 2017, and how life science strategic deal activity has been performing in recent years. In this report you can find an overview and analysis of: 
  • Trends for Biopharma IPOs
  • Deal activity for strategic partnership and M&A
  • Medical Devices, Diagnostics & Digital Health Analysis
  • Biopharma market trends in Japan and China
  • Biopharma and Medtech market trends in Europe
Download your free report to fuel your next transformative transaction.
    •  
    • General market sentiment remains positive, albeit wavering
    • General market sentiment remains positive, albeit wavering
  • Biopharma public indices have shown gains over 1Q 2017, but remain rangebound since the decline of the 2014-15 bull market
    • Biopharma public indices have shown gains over 1Q 2017, but remain rangebound since the decline of the 2014-15 bull market
    • Biopharma public indices have shown gains over 1Q 2017, but remain rangebound since the decline of the 2014-15 bull market
    Biopharma public indices have shown gains over 1Q 2017, but remain rangebound since the decline of the 2014-15 bull market
  • Biopharma public indices have shown gains over 1Q 2017, but remain rangebound since the decline of the 2014-15 bull marke
  • Biopharma public indices have shown gains over 1Q 2017, but remain rangebound since the decline of the 2014-15 bull marke
  • Biopharma stocks have room for gain following overall declines since 2015 peak 
  • Biopharma stocks have room for gain following overall declines since 2015 peak 
  • Biopharma stocks have room for gain following overall declines since 2015 peak 
  • Biopharma stocks have room for gain following overall declines since 2015 peak 
  • Biopharma stocks have room for gain following overall declines since 2015 peak 
*Please fill in the form on the right to get your free report